Recently, the phase 3 clinical trial results of T cell receptor (TCR) therapy, tebentafusp, have been released. The results showed that it reached the primary endpoint in the treatment of metastatic uvealRead More…
CD38 protein, which was discovered in 1980, is a type II transmembrane glycoprotein with a size of 46 kDa. The ligand of CD38 is CD31, also known as PECAM-1, which is aRead More…
A team of researchers from the United States have found that an antibody that “embeds” influenza virus surface proteins can protect mice from a variety of influenza virus strains and is expectedRead More…
The high cost of cancer drugs makes it difficult for public and private health care systems to provide patients with up-to-date treatment. If this trend continues, it will be increasingly difficult forRead More…
B lymphocytes can only produce a proprietary antibody against an antigen determinant, so it has the characteristics of highly specific physical and chemical properties, single biological activity, strong binding specificity with antigenRead More…
The Antibodies are secreted by plasma cells transformed from B cells, and each B cell line can produce only one specific antigenic determinant. The antibody, produced from a single cell line, isRead More…
The outbreak of Ebola in 2014 in West Africa killed more than 11000 people. At the time, scientists were working on several experimental vaccines and treatments, but none of them were approvedRead More…
Scientists, from the German Cancer Research Center (DKFZ), have successfully reconstructed biomolecules in the form of images. The goal of the researchers is to create a mirror artificial protein synthesis system. InRead More…
Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the nanobody drug Cablivi (caplacizumab), combined with plasma exchange and immunosuppressive therapy. For the treatment ofRead More…